Skip to content

Effect of dexmedetomidine combined with ulinastatin on early neurological improvement and prognosis in patients undergoing acute ischemic stroke: a prospective, double-blind, randomized controlled clinical trial

Effect of dexmedetomidine combined with ulinastatin on early neurological improvement and prognosis in patients undergoing acute ischemic stroke: a prospective, single-blind, randomized controlled clinical trialEffect of dexmedetomidine combined with ulinastatin on early neurological improvement and prognosis in patients undergoing acute

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800020020
Enrollment
Unknown
Registered
2018-12-11
Start date
2019-02-01
Completion date
Unknown
Last updated
2018-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute ischemic stroke

Interventions

Group 2:saline
Group 1:dexmedetomidine+ulinastatin

Sponsors

Shunde Hospital of Southern Medical University (the first people's hospital of shunde)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. a large number of intracranial vascular occlusion caused by acute ischemic stroke confirmed by CT angiography, no cerebral hemorrhage; 2. aged 18-80 years old, male or female; 3. The informed consent form is signed by the patient or a legal relative; 4. The National Institutes of Health Stroke Scale (NIHSS) scores 6-30; 5. can perform interventional surgery under general anesthesia of tracheal intubation; 6. Start treatment after <8 hours after the onset of symptoms.

Exclusion criteria

Exclusion criteria: 1. Those who are unwilling to continue to receive trial treatment; 2. Patients who were comatose at admission (Glasgow coma score <8) 3. Those who are allergic to related anesthetics; 4. CT confirmed cerebral hemorrhage; 5. Patients with related mental illnesses before surgery, such as: dementia; 6, MRS = 4 before the disease; 7. A history of severe liver disease or severe kidney disease; 8. pregnant women; 9. a history of atrial electrophysiological instability, hemodynamic instability, heart rate below 60 beats / min or systolic blood pressure below 90mmHg. 10. There may be difficulty in intubation or damage to the airway; 11. lost to the visitor; 12. Combine the application of banned drugs or those that affect efficacy evaluation; 13. The original condition deteriorated and the test could not be completed.

Design outcomes

Primary

MeasureTime frame
NIHSS score;

Secondary

MeasureTime frame
Glasgow score;TICI grade;MMSE score;Modified Rankin Scale (MRS) score;Barthel index (BI) score;Intraoperative and postoperative complication;Arterial blood gas analysis;Use of Anesthetic drugs (type and total);Adverse reactions;

Countries

China

Contacts

Public ContactZhang Zhongqi

Shunde Hospital of Southern Medical University (the first people's hospital of shunde)

jxzzq11@139.com+86 13798682324

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026